Ambee Pharmaceuticals (DHA:AMBEEPHA) EPS without NRI: BDT (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:AMBEEPHA Ambee Pharmaceuticals Plc DHA:AMBEEPHA
18 GF Score
Price BDT791.00
View Full Analysis

What is Ambee Pharmaceuticals EPS without NRI?

Ambee Pharmaceuticals DHA:AMBEEPHA +2.51% 18 EPS without NRI is BDT as of . 20. GuruFocus rates DHA:AMBEEPHA with a GF Score™ of 18/100. Among 788 Drug Manufacturers companies, Ambee Pharmaceuticals ranks worse than 126903.43% on this metric.

Ambee Pharmaceuticals's earnings per share without non-recurring items for the six months ended in . 20 was BDT0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Ambee Pharmaceuticals's EPS without NRI or its related term are showing as below:

DHA:AMBEEPHA's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.6
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Ambee Pharmaceuticals's EPS (Diluted) for the six months ended in . 20 was BDT0.00.

Ambee Pharmaceuticals's EPS (Basic) for the six months ended in . 20 was BDT0.00.


Ambee Pharmaceuticals  (DHA:AMBEEPHA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ambee Pharmaceuticals EPS without NRI Related Terms


Ambee Pharmaceuticals EPS without NRI Historical Data

* Premium members only.

The historical data trend for Ambee Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ambee Pharmaceuticals EPS without NRI Chart

Ambee Pharmaceuticals Annual Data
Trend
EPS without NRI

Ambee Pharmaceuticals Semi-Annual Data
EPS without NRI

DHA:AMBEEPHA vs IMNPQ: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ambee Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ambee Pharmaceuticals PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ambee Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Ambee Pharmaceuticals's PE Ratio without NRI falls into.


DHA:AMBEEPHA
18GF Score
Ambee Pharmaceuticals Plc DHA:AMBEEPHA
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ambee Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS without NRI for the trailing twelve months (TTM) ended in . 20 was BDT

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of BDT mean?
Ambee Pharmaceuticals (DHA:AMBEEPHA) has a EPS without NRI of BDT as of . 20. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Ambee Pharmaceuticals and its competitors. According to the industry distribution chart, Ambee Pharmaceuticals ranks #999999 out of 788 companies in the Drug Manufacturers industry.
Is Ambee Pharmaceuticals' EPS without NRI too high?
Ambee Pharmaceuticals' current EPS without NRI is BDT. Based on the distribution chart, Ambee Pharmaceuticals ranks #999999 out of 788 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ambee Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Ambee Pharmaceuticals' EPS without NRI compare to IMNPQ?
According to the Drug Manufacturers industry distribution chart, Ambee Pharmaceuticals ranks #999999 out of 788 companies for EPS without NRI. This places Ambee Pharmaceuticals in the lower half of its industry. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Ambee Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambee Pharmaceuticals's current EPS without NRI is BDT. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambee Pharmaceuticals stock overvalued right now?
Ambee Pharmaceuticals (DHA:AMBEEPHA) has a current EPS without NRI of BDT. The current EPS without NRI is BDT. Ambee Pharmaceuticals' overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Ambee Pharmaceuticals (DHA:AMBEEPHA), the current EPS without NRI is BDT as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ambee Pharmaceuticals Business Description

Address 184/1 Tejgaon Industrial Area, Dhaka, BGD, 1208
Ambee Pharmaceuticals Plc formerly Ambee Pharmaceuticals Ltd manufactures a wide range of pharmaceutical products in Bangladesh. It is engaged in the business of manufacturing drugs and medicine and sales. Its products are sold in the form of tablets, capsules, liquids, gels, and injectables.
18GF Score

Get the complete analysis for DHA:AMBEEPHA

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT791.00
Price